STOCK TITAN

FENNEC PHARMACEUTICALS (FENC) SEC Filings, Oct-Nov 2025

FENC NASDAQ

Fennec Pharmaceuticals Inc. filings document formal disclosures for its commercial specialty pharmaceutical business, PEDMARK® product updates, and Nasdaq-listed common shares. Recent Form 8-K reports cover financial results, scientific presentations and investigator-sponsored studies involving sodium thiosulfate injection, and a license agreement resolving litigation tied to a proposed generic version of PEDMARK.

The company’s proxy materials cover director elections, board composition, executive compensation, equity awards, and shareholder voting matters. Other current reports disclose governance changes, registered common shares with no par value, and exhibits furnished with press releases concerning business, clinical, and product-related developments.

Rhea-AI Summary

Fennec Pharmaceuticals Inc. is offering 4,666,667 common shares at $7.50 per share in an underwritten public offering, for gross proceeds of $35,000,003 and estimated net proceeds of $32,400,002 before the underwriters’ option. The company has granted underwriters a 30‑day option to buy up to 700,000 additional shares. A concurrent non‑brokered LIFE offering in Canada may raise up to an additional $5,025,000 but is not registered under this prospectus. Fennec plans to use the combined proceeds primarily to repurchase and redeem its Petrichor convertible notes for about $21,729,455 and apply any remaining funds to working capital and general corporate purposes. Following this offering and the Concurrent LIFE Offering, 33,453,496 common shares will be outstanding, or 34,153,496 if the option is fully exercised, compared with 28,116,829 shares outstanding as of November 12, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.32%
Tags
prospectus
-
Rhea-AI Summary

Fennec Pharmaceuticals Inc. entered into an underwriting agreement to conduct an underwritten public offering of 4,666,667 common shares. The shares will be sold to the public at $7.50 per share and purchased by the underwriters from the company at $6.975 per share, with Fennec receiving the net proceeds. The company also granted the underwriters a 30-day option to buy up to an additional 700,000 shares at the public offering price, less underwriting discounts and commissions.

The transaction is being carried out under an effective shelf registration statement on Form S-3, using a prospectus supplement and related prospectus. Piper Sandler & Co. and Craig-Hallum Capital Group LLC are acting as representatives of the underwriters, and the closing of the offering is expected on November 17, 2025, subject to customary conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.32%
Tags
current report
-
Rhea-AI Summary

Fennec Pharmaceuticals filed a preliminary prospectus supplement for a primary offering of common shares. The company expects to use initial net proceeds to repurchase and redeem its outstanding Petrichor convertible notes, with an aggregate principal amount (inclusive of PIK interest) of approximately $19,769,076, which bear interest at prime (floor 3.5%) plus 4.5% and mature on August 19, 2027.

The offering includes a 30‑day option for underwriters to purchase additional shares. Fennec also plans a concurrent, non‑brokered Canadian LIFE offering on the same terms with certain existing institutional shareholders, which may close at the same time or shortly after and would dilute participants in this offering if completed. The common shares trade on Nasdaq as “FENC” and TSX as “FRX”; the last reported Nasdaq sale price was $7.78 on November 12, 2025. Shares outstanding were 28,116,829 as of November 12, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
prospectus
Rhea-AI Summary

Fennec Pharmaceuticals (FENC) reported Q3 2025 results with PEDMARK net product sales of $12,462 (up from $6,974 a year ago). For the nine months, net product sales were $30,865 versus $21,655 in 2024. Q3 operating loss was $(189) and net loss was $(638), or $(0.02) per share.

Cash and cash equivalents were $21,947, total assets $49,261, and total liabilities $53,753, resulting in a stockholders’ deficit of $(4,492). The balance sheet reflects a term loan of $18,206 and accrued PIK interest of $1,271 under the Petrichor notes; following December 2024 redemptions, $19,477 remained outstanding as of September 30, 2025. Operating cash flow for the nine months was $(6,511); financing cash flow was $1,824.

The company continues to account for its 2024 Norgine license—approximately $43,000 was received upfront, with $24,561 recorded as long‑term contract liability. As of November 10, 2025, common shares outstanding were 28,116,829.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
quarterly report
-
Rhea-AI Summary

Fennec Pharmaceuticals (FENC) reported an insider transaction on a Form 4. Director Rosty Raykov sold 10,000 common shares on 11/05/2025 at $8.10 per share in an open-market sale. Following the transaction, he beneficially owns 82,318 shares, held directly.

The sale was made pursuant to a Rule 10b5-1 trading plan dated August 23, 2024, indicating pre‑arranged trading parameters.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
insider
-
Rhea-AI Summary

Fennec Pharmaceuticals (FENC) reported an insider equity change. Director Rosty Raykov acquired 5,208 common shares on 10/31/2025 at $0, reflecting the release of restricted shares previously awarded on 3/31/2023 and 5/16/2024. Following this transaction, Raykov beneficially owns 92,318 shares, held directly.

The filing lists no derivative transactions in Table II.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.60%
Tags
insider
Rhea-AI Summary

Fennec Pharmaceuticals (FENC) Form 4: Chief Financial Officer Robert Andrade reported acquiring 2,430 common shares at $0 on 10/31/2025. The filing states these shares were released from restriction related to awards granted on 3/31/2023 and 5/16/2024. Following the transaction, Andrade beneficially owns 173,104 shares, held directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.60%
Tags
insider
-
Rhea-AI Summary

Fennec Pharmaceuticals (FENC) reported an insider transaction by a director on 10/10/2025. The director exercised 4,062 options at a $1.23 exercise price under a 10b5-1 plan adopted on May 19, 2025, acquiring the same number of common shares. To cover taxes from the exercise, the insider sold 1,775 shares at $9.24. Following these transactions, the insider beneficially owned 57,079 common shares directly and held 174,344 derivative securities (options) after the reported activity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.86%
Tags
insider
-
Rhea-AI Summary

Fennec Pharmaceuticals (FENC) filed a Form 144 notifying a proposed sale of 1,775 common shares with an aggregate market value of $16,401.00. The shares are scheduled for sale approximately on 10/10/2025 on NASDAQ. The filing shows the shares were acquired the same day, 10/10/2025, by stock option exercise from the issuer and paid in cash. There were 27,831,698 shares outstanding noted for the class. No securities were reported sold in the prior three months. The filer affirms they are not aware of undisclosed material adverse information and the notice contains the standard attestation language regarding trading plans and criminal penalties for false statements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
other
Rhea-AI Summary

Fennec Pharmaceuticals (FENC) insiders filed a Form 4 reporting multiple open-market sales of common stock across 10/07/2025 to 10/09/2025

Reporting entities tied to Southpoint (Southpoint Capital Advisors LP/LLC, Southpoint GP entities and John S. Clark II) sold a total of 67,114 shares in three tranches at weighted-average prices of approximately $9.5871, $9.4732, and $9.3461. Reported beneficial ownership after each trade was 4,050,314, 4,030,709, and 4,010,100 shares respectively. The filing explains that the shares are held directly by Southpoint Master Fund, LP and that the reporting persons disclaim beneficial ownership except for pecuniary interest.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.15%
Tags
insider

FAQ

How many FENNEC PHARMACEUTICALS (FENC) SEC filings are available on StockTitan?

StockTitan tracks 149 SEC filings for FENNEC PHARMACEUTICALS (FENC), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for FENNEC PHARMACEUTICALS (FENC)?

The most recent SEC filing for FENNEC PHARMACEUTICALS (FENC) was filed on November 16, 2026.